当前位置: X-MOL 学术medRxiv. Allergy Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.
medRxiv - Allergy and Immunology Pub Date : 2020-06-11 , DOI: 10.1101/2020.06.09.20127050
Edward P Gniffke , Whitney E Harrington , Nicolas Dambrauskas , Yonghou Jiang , Olesya Trakhimets , Vladimir Vigdorovich , Lisa Frenkel , D Noah Sather , Stephen E P Smith

High throughput serological tests that can establish the presence and functional activity of anti-SARS-COV2 antibodies are urgently needed. Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). First, we detected anti-trimer IgGs in 22/24 and anti-RBD IgGs in 21/24 COVID+ subjects at a median of 36 (range 14-73) days following documented SARS-CoV-2 RNA (+) secretions. Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels. Depletion of trimer-reactive Igs from plasma reduced ACE2-trimer inhibitory capacity to a greater degree than depletion of RBD-reactive Igs, suggesting that inhibitory antibodies act by binding both within and outside of the RBD. Amongst the 24 subjects, presence of fever was associated with higher levels of anti-trimer IgG and inhibition of binding to human ACE2. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.

中文翻译:

在基于微球的抑制试验中,来自回收的COVID19受试者的血浆抑制刺突蛋白与ACE2的结合。

迫切需要能够确定抗SARS-COV2抗体的存在和功能活性的高通量血清学测试。在这里,我们介绍了基于微球的流式细胞术,可量化血浆中的抗尖峰IgG和血浆抑制尖峰蛋白与血管紧张素转化酶2(ACE2)结合的能力。首先,在记录SARS-CoV-2 RNA(+)分泌后的中位数36天(14-73天)内,我们在22/24个COVID +受试者中检测了抗三聚体IgG,在21/24个COVID +受试者中检测了抗RBD IgG。接下来,我们发现来自所有具有抗三聚体IgG的22/24受试者的血浆抑制ACE2-三聚体的结合程度大于对照,并且抑制程度与抗三聚体IgG水平相关。血浆中三聚体反应性Ig的消耗比RBD反应性Igs的消耗更大程度地降低了ACE2-三聚体的抑制能力,这表明抑制性抗体通过结合RBD内部和外部发挥作用。在24名受试者中,发烧与抗三聚体IgG水平升高和与人ACE2结合的抑制有关。这种抑制分析可广泛用于定量无细胞分析系统中回收的COVID19患者或疫苗接种者的功能抗体反应。
更新日期:2020-06-11
down
wechat
bug